Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
Zhan et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102359
https://c19early.org/zhan2.html